Prevention & care

Liver cancer: primary tumors, metastases, liver function, AFP, and local treatments

10 sources · Latest source check 2026-10-08 UTC

On this page

Primary liver cancer begins in the liver; hepatocellular carcinoma is the common adult form. Intrahepatic bile-duct cancer begins in ducts inside the liver and belongs to a different family. Cancer spreading into the liver from another organ retains its original tissue identity. This page mainly explains adult primary-cancer literacy.[1][2]

Location and tissue origin are separate labels

Location and tissue origin are separate labels
Finding	Meaning
Hepatocellular carcinoma	Primary adult cancer arising from liver cells.[1][2]
Intrahepatic cholangiocarcinoma	Bile-duct cancer within the liver.[1]
Liver metastasis	Cancer arriving from another primary site.[2]
Benign mass	Examples include hemangioma and focal nodular hyperplasia.[2]
Childhood liver tumor	Different families and pediatric treatment pathways.[1]

Rare liver cancers do not share one adult-HCC evidence base

ACS describes fibrolamellar carcinoma, blood-vessel sarcomas and childhood hepatoblastoma as distinct cancers. The presence or absence of cirrhosis also differs across families. A study labeled HCC should not be assumed to apply equally to every rare liver tumor.[2]

Colorectal cancer in the liver is still colorectal cancer

ACS explains that secondary liver cancers are treated according to their original site. A liver scan finding therefore needs its primary origin clarified. Comparing primary-HCC outcomes with outcomes for selected colorectal liver metastases would compare different diseases and care populations.[2]

Benign findings can still need assessment

ACS describes benign liver findings that can cause symptoms or resemble cancer. A benign label alone does not establish whether follow-up is needed.[2]

Chronic liver disease changes probability without proving cancer

NCI identifies hepatitis B or C, cirrhosis, heavy alcohol exposure, smoking, metabolic liver injury and certain inherited conditions among risk contexts. Cancer can occur without a recognized risk. A risk factor is not a tissue diagnosis or a reliable explanation of one individual’s illness.[3]

Reducing a liver risk is different from treating an existing tumor

NCI describes prevention through reducing relevant exposures, preventing HBV infection and treating chronic hepatitis when appropriate. These measures address risk; they do not replace investigation of a mass. The linked hepatitis and liver-disease articles explain their separate testing, prevention and care settings.[3]

Primary and secondary liver cancers can cause overlapping symptoms

NHS describes jaundice, unexplained weight loss, abdominal swelling or pain and feeling full early. Other conditions can cause similar changes. New yellowing of skin or eyes warrants urgent assessment. Symptoms alone cannot determine whether a finding is HCC, bile-duct cancer, metastasis or another condition.[4]

AFP can be normal in cancer and raised without cancer

NCI explains that AFP can rise in hepatitis, cirrhosis and other cancers, and can remain normal in liver cancer. It cannot establish or exclude cancer alone. A marker trend must be interpreted with imaging, clinical context and the actual suspected tissue family.[5]

Selected liver cancers can be diagnosed without a needle biopsy

NCI describes ultrasound, contrast imaging and tissue sampling, noting that biopsy is not always required. Some diagnoses rely on specific imaging findings. This exception does not mean that any incidental liver spot can be named or treated from an isolated picture. Ask why imaging is sufficient or what sampling could resolve.[5]

The remaining organ’s function matters as well as cancer extent

NCI lists liver function, cirrhosis and general health alongside disease extent when describing prognosis and treatment options. A small tumor in a severely impaired liver can pose a different care problem from a similarly sized tumor in a well-functioning liver. Tumor size alone cannot rank those situations.[5]

BCLC combines cancer findings with liver function and overall condition

NCI describes the Barcelona Clinic Liver Cancer framework as one of several staging systems. It incorporates disease spread, liver performance, symptoms and general condition. Ask which framework is being used and which findings determine its category; a label cannot replace the underlying measurements.[6]

Screening, diagnostic assessment and recurrence checks have different purposes

NCI distinguishes testing before symptoms from investigating an abnormal result. False-positive results can lead to anxiety and procedures; false negatives can delay assessment. A normal surveillance result is not a guarantee against later disease or a reason to dismiss new symptoms.[7]

Resection and transplantation solve different problems

NCI distinguishes removing part of the liver from replacing the liver with a donated organ. Both require specialist selection. Possible regrowth of remaining liver tissue does not establish that every person can safely undergo resection; cancer extent and functioning liver reserve still matter.[9]

Ablation and embolization target tumors in different ways

NCI describes procedures that directly destroy tissue and procedures that reduce tumor blood supply. TACE adds an anticancer medicine to arterial embolization. These are specific clinical interventions, not evidence that drinking alcohol, routine heat exposure or a “liver detox” treats cancer. Local treatment still has risks.[9]

Systemic treatment and symptom control need their intended goals

NCI describes targeted or immune medicines, radiation and clinical trials in selected settings. The appropriate care depends on disease family, extent and health. Ask about survival, recurrence, serious adverse effects and daily function, alongside symptom relief and support. This overview does not select or sequence cancer medicines.[9]

A later guidance update prevents treating an older document as final

AASLD’s official guidance page links both its HCC practice guidance and a critical update. The update’s clinical text was not accessible in this retrieval. Its existence is recorded as a currentness limit; no uninspected updated treatment recommendation is inferred from its title.[10]

Evidence & uncertainty

Evidence depends on the cell family, underlying liver disease and ability to tolerate treatment. An early-detection test’s sensitivity does not by itself prove a mortality benefit. Older patient explanations and selected review findings cannot provide a complete current ranking of cancer treatments.[7][8]

Selected-source overview · Independent review pending

Published questions

Is colorectal cancer that spreads to the liver primary liver cancer?

Selected-source overview · Independent review pending. Read the evidence context.

It retains its colorectal tissue origin.[2]

Evidence behind this answer

What Is Liver Cancer?
professional association explanation · 2025
Selected relevant original official page passages inspected · Primary, secondary, rare and benign liver tumors